Michael M. Haderlie, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 233 S. Pleasant Grove Blvd, Suite 203, Pleasant Grove, UT 84062 Phone: 801-785-4622 Fax: 801-785-4623 |
Sierra Baird, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 801 S Pleasant Grove Blvd # 200, Pleasant Grove, UT 84062 Phone: 801-361-8589 |
Ms. Rebecca Lynn Scott, SCHOOL PSYCHOLOGIST Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 867 S. 800 W., Pleasant Grove, UT 84062 Phone: 801-785-9019 |
Tanya Colledge, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1392 W State Rd, Pleasant Grove, UT 84062 Phone: 801-318-8157 |
Evelyn Rollins Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1344 W State Rd, Pleasant Grove, UT 84062 Phone: 801-785-8870 Fax: 801-785-9454 |
Kelsey Elizabeth Clews, M.A., PSY.D Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2702 N 900 W, Pleasant Grove, UT 84062 Phone: 904-501-9588 |
Mindy Pearson Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 233 S Pleasant Grove Blvd Ste 203, Pleasant Grove, UT 84062 Phone: 801-785-4622 Fax: 801-785-4623 |
Dr. Christopher Elson Peck, PH.D. Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 233 S Pleasant Grove Blvd Ste 203, Pleasant Grove, UT 84062 Phone: 801-785-4622 Fax: 801-785-4623 |
News Archive
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.
Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.
Between the flap at the Susan G. Komen for the Cure and the squall about the Obama administration's directive that health insurance plans cover the cost of birth control, contraception is shaping up as one of the year's biggest political land mines.
› Verified 4 days ago